PRIMA-1Met induces apoptosis in Waldenström’s Macroglobulinemia cells independent of p53

Cancer Biology and Therapy

Volumn 16, Issue 5, 2015, Pages 799-806

  Sobhani, Mona ^a,b   Abdi, Jahangir ^a,b   Manujendra, Saha N ^a,b   Chen, Christine ^c   Chang, Hong ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Apoptosis; Dexamethasone or bortezomib; p53; p73; PRIMA 1Met; Waldenstr m s Macroglobulinemia

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; PRIMA 1MET; PROTEIN BCL XL; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 2-HYDROXYMETHYL-2-METHOXYMETHYLAZABICYCLO(2.2.2)OCTAN-3-ONE; QUINUCLIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; UPREGULATION; WALDENSTROEM MACROGLOBULINEMIA; GENETICS; METABOLISM; TUMOR CELL LINE; WALDENSTROM MACROGLOBULINEMIA;

APOPTOSIS; CELL LINE, TUMOR; HUMANS; QUINUCLIDINES; TUMOR SUPPRESSOR PROTEIN P53; WALDENSTROM MACROGLOBULINEMIA;

EID: 84943744672     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1026482     Document Type: Article

References (32)

1. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, et al. Diagnosis and Management of Waldenstr? m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. Mayo Clin Proc 2010; 85: 824-833; PMID: 20702770; http://dx. doi. org/10. 4065/mcp. 2010. 0304.
2. Gertz MA. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 503-510; PMID: 22508368; http://dx. doi. org/10. 1002/ajh. 23192.
3. Shaheen SP, Talwalkar SS, Lin P, Medeiros LJ. Waldenström macroglobulinemia: a review of the entity and its differential diagnosis. Adv Anat Pathol 2012; 19: 11-27; PMID: 22156831; http://dx. doi. org/10. 1097/PAP. 0b013e31824019d0.
4. Gertz M. Waldenström macroglobulinemia: my way. Leuk. Lymphoma 2013; 54: 464-471; http://dx. doi. org/10. 3109/10428194. 2012. 717173.
5. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137: 413-431; PMID: 19410540; http://dx. doi. org/10. 1016/j. cell. 2009. 04. 037.
6. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130; PMID: 19407794; http://dx. doi. org/10. 1038/nature07986.
7. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011; 8: 25-37; PMID: 20975744; http://dx. doi. org/10. 1038/nrclinonc. 2010. 174.
8. Bykov VJN, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-288; PMID: 11875500; http://dx. doi. org/10. 1038/nm0302-282.
9. Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res 2011; 17: 2830-2841; PMID: 21415220; http://dx. doi. org/10. 1158/1078-0432. CCR-10-3168.
10. Bao W, Chen M, Zhao X, Kumar R, Spinnler C, Thullberg M, Issaeva N, Selivanova G, Strömblad S. PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle 2011; 10: 301-307; PMID: 21239882; http://dx. doi. org/10. 4161/cc. 10. 2. 14538.
11. Liang Y, Besch-Williford C, Hyder SM. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int J Oncol 2009; 35: 1015-1023; PMID: 19787255.
12. Nahi H, Selivanova G, Lehmann S, Möllgárd L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol 2008; 141: 445-453; PMID: 18341636; http://dx. doi. org/10. 1111/j. 1365-2141. 2008. 07046. x.
13. Lehmann S, Bykov VJN, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, et al. Targeting p53 in vivo: a first-inhuman study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633-3639; PMID: 22965953; http://dx. doi. org/10. 1200/JCO. 2011. 40. 7783.
14. Lambert JMR, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJN. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15: 376-388; PMID: 19411067; http://dx. doi. org/10. 1016/j. ccr. 2009. 03. 003.
15. Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C, Merup M. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 2004; 127: 285-291; PMID: 15491287; http://dx. doi. org/10. 1111/j. 1365-2141. 2004. 05210. x.
16. Supiot S, Zhao H, Wiman K, Hill RP, Bristow RG. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol 2008; 86: 407-411; PMID: 18237796; http://dx. doi. org/10. 1016/j. radonc. 2008. 01. 001.
17. Ali D, Jönsson-Videsäter K, Deneberg S, Bengtzén S, Nahi H, Paul C, Lehmann S. APR-246 exhibits antileukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Eur J Haematol 2011; 86: 206-215; PMID: 21114538; http://dx. doi. org/10. 1111/j. 1600-0609. 2010. 01557. x.
18. Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther 2013; 12: 2331-2341; PMID: 24030633; http://dx. doi. org/10. 1158/1535-7163. MCT-12-1166.
19. Lambert JMR, Moshfegh A, Hainaut P, Wiman KG, Bykov VJN. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 2010; 29: 1329ne (20); http://dx. doi. org/10. 1038/onc. 2009. 425.
20. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113 (Pt 10): 16610 (10).
21. Agarwal A, Ghobrial IM. The bone marrow microenvironment in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013; 13, 218-221; PMID: 23490994; http://dx. doi. org/10. 1016/j. clml. 2013. 02. 006.
22. Messina RL, Sanfilippo M, Vella V, Pandini G, Vigneri P, Nicolosi ML, Gianí F, Vigneri R, Frasca F. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. Int J Cancer 2012; 130: 2259-2270; PMID: 21647879; http://dx. doi. org/10. 1002/ijc. 26228.
23. Aryee DNT, Niedan S, Ban J, Schwentner R, Muehlbacher K, Kauer M, Kofler R, Kovar H. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma. Br J Cancer 2013; 109: 2696-2704; PMID: 24129240; http://dx. doi. org/10. 1038/bjc. 2013. 635.
24. Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R. Molecular pathogenesis of Waldenström's macroglobulinemia. Haematologica 2012; 97: 1281-1290; PMID: 22773606; http://dx. doi. org/10. 3324/haematol. 2012. 068478.
25. Nahi H, Merup M, Lehmann S, Bengtzen S, Möllgárd L, Selivanova G, Wiman KG, Paul C. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 2006; 132: 230-236; PMID: 16398657.
26. Tessoulin B, Descamps G, Moreau P, MaG S, Lod L, Godon C, Marionneau-Lambot S, Oullier T, Le Gouill S, Amiot M, et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood 2014; 124: 1626 et al; http://dx. doi. org/10. 1182/blood-2014-01-548800.
27. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011; 12: 471-480; PMID: 22204764.
28. Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002; 9: 6-19; PMID: 11803370; http://dx. doi. org/10. 1038/sj. cdd. 4400969.
29. Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MAZ, et al. Establishment of BCWM. 1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol 2007; 35: 1366-1375; PMID: 17761288.
30. - 1. Blood 2011; 117: e190-197; PMID: 21415268; http://dx. doi. org/10. 1182/blood-2010-12-326868.
31. - 2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13: 621-629; PMID: 17255285.
32. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681; PMID: 16968952; http://dx. doi. org/10. 1124/pr. 58. 3. 10.